TickerFacts.

Exelixis, Inc. (EXEL): Shareholders' Equity

Annual figures by period end, from SEC filings.

Restated years: each year's figure is from the latest filing that reports it. The company later restated the year ended 2012-12-31 (for example after a spin-off or a discontinued operation), while the year before it was last reported on the old basis. Changes across those points are marked n/c (not comparable), and growth rates are not computed across them.

$2.16B
As of 2026-01-02, Fiscal 2025
$1.84B
As of 2026-07-03
-4.6%
3-year compound annual growth
+2.8%
5-year compound annual growth
$2.49B2009-12-31: -$163.72M2010-12-31: -$228.32M2011-12-31: $90.63M2012-12-31: $238.13M2013-12-31: $14.50M2014-12-31: -$159.32M2015-12-31: -$140.81M2016-01-01: -$140.81M2016-12-30: $89.32M2016-12-31: $89.32M2017-12-29: $284.96M2018-12-28: $1.29B2020-01-03: $1.69B2021-01-01: $1.88B2021-12-31: $2.21B2022-12-30: $2.49B2023-12-29: $2.26B2025-01-03: $2.24B2026-01-02: $2.16B$2.16B
2009-12-31 Shareholders' Equity (USD) 2026-01-02
Period endedShareholders' EquityChange YoYSource filing
2026-01-02, Fiscal 2025$2.16B-3.7%2026-02-10, Balance as of period end
2025-01-03, Fiscal 2024$2.24B-0.9%2026-02-10, Balance as of period end
2023-12-29$2.26B-9.0%2026-02-10, Balance as of period end
2022-12-30$2.49B+12.6%2025-02-11, Balance as of period end
2021-12-31$2.21B+17.6%2024-02-06, Balance as of period end
2021-01-01, Fiscal 2020$1.88B+11.5%2023-02-07, Balance as of period end
2020-01-03, Fiscal 2019$1.69B+31.0%2022-02-18, Balance as of period end
2018-12-28$1.29B+351.8%2021-02-11, Balance as of period end
2017-12-29$284.96M+219.0%2020-02-25, Balance as of period end
2016-12-31$89.32Mn/a2017-02-27, Balance as of period end
2016-12-30$89.32Mn/m2019-02-22, Balance as of period end
2016-01-01, Fiscal 2015-$140.81Mn/a2018-02-26, Balance as of period end
2015-12-31-$140.81Mn/m2017-02-27, Balance as of period end
2014-12-31-$159.32Mn/m2017-02-27, Balance as of period end
2013-12-31$14.50M-93.9%2017-02-27, Balance as of period end
2012-12-31$238.13Mn/c2017-02-27, Balance as of period end
2011-12-31$90.63Mn/m2014-02-20, Balance as of period end
2010-12-31-$228.32Mn/m2013-02-21, Balance as of period end
2009-12-31-$163.72Mn/a2012-02-22, Balance as of period end

Shareholders' Equity at similar companies

Companies with the same SEC industry code (Biological Products, (No Diagnostic Substances)), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

CompanyYear endedShareholders' EquityChange YoY
Exelixis, Inc. (EXEL)2026-01-02$2.16B-3.7%
Qiagen N.V. (QGEN)2025-12-31$3.78B+5.9%
Moderna, Inc. (MRNA)2025-12-31$8.65B-20.6%
Neurocrine Biosciences Inc (NBIX)2025-12-31$3.25B+25.6%
Halozyme Therapeutics, Inc. (HALO)2025-12-31$48.81M-86.6%
Bio-Techne Corp (TECH)2026-06-30$2.11B+9.9%
Novavax Inc (NVAX)2025-12-31-$127.75Mn/m
BioCryst Pharmaceuticals Inc (BCRX)2025-12-31-$119.15Mn/m
Repligen Corp (RGEN)2025-12-31$2.11B+6.8%

Compare EXEL, QGEN, MRNA, NBIX side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗